About Moebius medical ltd.

About company

Moebius Medical is developing MM-II, a novel liposome-based bio-lubricant for long-term treatment of osteoarthritis. Based on the clinical data from its recently completed first-in-man study, MM-II shows significant promise as the next generation intra-articular treatment for OA. MM-II`s success is due to its unique composition of liposomes, which act as "biological ball bearings". Its structure and superior mechanical lubrication properties facilitate cartilage surface gliding, thus preventing further wear and friction, as well as subsequent joint damage.